<DOC>
	<DOC>NCT00033215</DOC>
	<brief_summary>To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population</brief_summary>
	<brief_title>A Phase 1 Study of S-3304 in Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>S 3304</mesh_term>
	<criteria>Inclusion criteria: Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s) Must be able to tolerate oral medication Exclusion criteria Patients with other serious illnesses Patients who are receiving treatments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>neovascularization</keyword>
	<keyword>matrix metalloproteinases</keyword>
	<keyword>antiangiogenesis</keyword>
	<keyword>type IV collagenases</keyword>
</DOC>